Mitochondrial Oxidative Phosphorylation System Dysfunction in Schizophrenia.

dc.contributor.authorMorén Núñez, Constanza
dc.contributor.authorOlivares Berjaga, David
dc.contributor.authorMartínez Pinteño, Albert
dc.contributor.authorBioque Alcázar, Miquel
dc.contributor.authorRodriguez Ferret, Natalia
dc.contributor.authorGassó Astorga, Patricia
dc.contributor.authorMartorell, Lourdes
dc.contributor.authorParellada Rodón, Eduard
dc.date.accessioned2026-02-27T18:39:45Z
dc.date.available2026-02-27T18:39:45Z
dc.date.issued2025-05-06
dc.date.updated2026-02-27T18:39:45Z
dc.description.abstractSchizophrenia (SCZ) is a severe, chronic mental disorder of unknown etiology and limited therapeutic options. Bioenergetic deficits in the oxidative phosphorylation system (OXPHOS) during early postnatal brain development may underlie disrupted neuronal metabolism and synaptic signaling, contributing to the neurodevelopmental and behavioral disturbances observed in patients. This narrative review summarizes updated evidence linking mitochondrial-OXPHOS dysfunction to SCZ pathophysiology. The novelty lies in the focus on OXPHOS dysfunction at the enzymatic/functional level, rather than on genetic, transcriptional, or oxidative parameters. While complex I impairment has long been highlighted and proposed as a peripheral marker of the disease, recent studies also report alterations in other OXPHOS complexes and their precursors. These findings suggest that OXPHOS dysfunction is not isolated to a single enzymatic component but affects broader mitochondrial function, alongside oxidative stress, contributing to disease progression through mechanisms involving apoptosis, accelerated aging, and synaptic deterioration. OXPHOS dysfunction in both central and peripheral tissues further supports its relevance to SCZ. Overall, the literature points to mitochondrial OXPHOS abnormalities as a significant biological feature of SCZ. Whether these alterations are causal factors or consequences of disease processes remains unclear. Understanding OXPHOS dysregulation may open new avenues for targeted therapies.
dc.format.extent20 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec764842
dc.identifier.issn1661-6596
dc.identifier.pmid40362652
dc.identifier.urihttps://hdl.handle.net/2445/227720
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms26094415
dc.relation.ispartofInternational Journal of Molecular Sciences, 2025, vol. 26, num.9
dc.relation.urihttps://doi.org/10.3390/ijms26094415
dc.rightscc-by (c) Morén, C et al., 2025
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.classificationEsquizofrènia
dc.subject.classificationMitocondris
dc.subject.classificationMetabolisme
dc.subject.otherSchizophrenia
dc.subject.otherMitochondria
dc.subject.otherMetabolism
dc.titleMitochondrial Oxidative Phosphorylation System Dysfunction in Schizophrenia.
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
914851.pdf
Mida:
486 KB
Format:
Adobe Portable Document Format